Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center

Leuk Lymphoma. 2021 Sep;62(9):2288-2291. doi: 10.1080/10428194.2021.1913141. Epub 2021 Apr 24.

Authors

Cecilia Carpio^{1

2}, Gloria Iacoboni^{1

2}, Guillermo Villacampa³, Eva Catalá^{1

2}, Sabela Bobillo^{1

2}, Ana Pérez^{1

2}, Moraima Jiménez^{1

2}, Laura Segura^{1

2}, Mireia Olivé^{1

2}, Anna Farriols^{1

2}, Pau Abrisqueta^{1

2}, David Valcárcel^{1

2}, María Josep Carreras^{1

2}, Francesc Bosch^{1

2}, Pere Barba^{1

2}

Affiliations

¹ Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain.
² Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

PMID: 33899648
DOI: 10.1080/10428194.2021.1913141

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD19
B-Lymphocytes
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Lymphoma, B-Cell* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen* / genetics

Substances

Antigens, CD19
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen